Home > Poor prognosis for T2D patients on loop diuretics in addition to SGLT2 inhibitor

Poor prognosis for T2D patients on loop diuretics in addition to SGLT2 inhibitor

Presented By
Prof. Pierpaolo Pellicori, University of Glasgow, United Kingdom
Conference
EASD 2020
Trial
EMPA-REG OUTCOME
Type 2 diabetes (T2D) patients with cardiovascular disease being treated with a sodium-glucose transport protein 2 (SGLT2) inhibitor have poorer outcomes if they also use loop diuretics. The poor prognosis also holds true for T2 diabetics who have not been diagnosed with heart failure (HF). An analysis of the EMPA-REG OUTCOME trial (NCT01131676) compared T2D patients without HF who received loop diuretics in addition to the SGLT2 inhibitor empagliflozin (n=755) with T2D patients without HF and without loop diuretics (n=5,559), as well as T2D patients with HF taking both drugs (n=706) [1]. The results, presented by Prof. Pierpaolo Pellicori (University of Glasgow, United Kingdom), showed no significant interaction between loop diuretic use and HF for all endpoints studied. The baseline patient characteristics did differ significantly for some meas...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on